COMP <GO>
ZJYL vs SMTI // EV/EBITDA & P/E VALUATION
JIN MEDICAL INTERNATIONAL LTD. (Class A) (NASDAQ) VS. Sanara MedTech Inc. (NASDAQ) • 15-METRIC TALLY: ZJYL 1
— SMTI 8
▲ EV/EBITDA & P/E VALUATION LEADER: SMTI
LAST: $1.86 (-2.10%) • MKT CAP: $294.2M
valuation
47.1x
LAST: $32.92 (+0.11%) • MKT CAP: $302.4M
valuation
29.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ZJYL VS. SMTI)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ZJYL | SMTI | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 29.20% | 92.70% | -63.50 | SMTI | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 16.30% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 47.1x | 29.5x | +17.60 | SMTI | /valuation <GO> |
| Free Cash Flow Yield | -1.27% | 0.71% | -1.98 | SMTI | /fcf-yield <GO> |
| Operating Margin | 2.90% | 7.10% | -4.20 | SMTI | /operating-margins <GO> |
| Net Profit Margin | 5.80% | 36.40% | -30.60 | SMTI | /net-margins <GO> |
| Revenue Growth (YoY) | -12.00% | 19.00% | -31.00 | SMTI | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 3.25 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 4/9 | 7/9 | -3.00 | SMTI | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.0 | 27.3 | +33.62 | ZJYL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 6.8x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $294.2M | $302.4M | -$8.2M | SMTI | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ZJYL REV | SMTI REV | ZJYL GROSS % | SMTI GROSS % | ZJYL FCF | SMTI FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $20.7M | $103.1M | 29.2% | 92.7% | -$3.7M | $2.2M |
| FY 2024 | $23.5M | $86.7M | 40.4% | 90.6% | -$1.4M | -$229.6K |
| FY 2023 | $19.8M | $65.0M | — | — | $3.1M | -$3.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ZJYL // BETA —
SMTI // BETA —